Tags: Chemical Compound, Chemical Substance.

Dacomitinib (PF-00299804) is an experimental drug candidate under development by Pfizer for the treatment of non-small-cell lung carcinoma. It is a selective and irreversible inhibitor of EGFR.Dacomitinib has advanced to several Phase III clinical trials. The results of the first trials were disappointing with a failure to meet the study goals Additional Phase III trials are ongoing.

Dacomitinib.svg
IUPAC name
(2E)-N-4-[(3-Chloro-4-fluorophenyl)amino]-7-methoxy-6-quinazolinyl-4-(1-piperidinyl)-2-butenamide

Loading...

This page contains content from the copyrighted Wikipedia article "Dacomitinib"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.